Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(NASDAQ: CLRX) and Medytox Solutions, Inc. (OTCQB: MMMS) ("Medytox") have entered into a non-binding letter of intent to negotiate a potential business combination.
http://yhoo.it/17jG16Z
That is pretty amazing. Star Trek here we come.
3DPI does the simple cell phone they printed actually work?
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received commitments from two dedicated health care funds to purchase an aggregate of $12 million of the Company’s common stock in a registered direct offering.
OTC I wasn't trying to start any shit, was just stating what I saw at the time. I'd feel better if I didn't live in RI. We're getting set to get slammed.
$RMTI triferic approved!
I am talking about $NVIV.
More selling than buying today.
$APPY Response from APPY Investor Relation Manager Jedidiah Mahan:
Jan 22 at 4:57 PM
David,
When we sent in the supplement in December, there were 53 days left of the 120 day goal that FDA has set for De Novo submissions, as Steve mentioned in the last investor call. Assuming that they achieve their goal, we would expect to hear from them by the end of January. For clarity, this is a performance goal set by the FDA, not necessarily a requirement.
Best,
Jed
Jedidiah Mahan
Investor Relations Manager
cid:27EB97BC-1228-4DF7-881B-DA86F2FEC85F@sd.cox.net
$CUR I'm in. Company seems to be firing on all cylinders.
$CUR Jason Napodano, CFA ?@JNapodano 51m51 minutes ago SocialProtect : OK
There was no "delay" in $CUR data. Lock will take place late January. Data still Q1, which is what I always said >>
from twitter
that allows its customers to buy new stock against a sale of other stock before the sale has cleared.
Yes you can do that at Fidelity but you still have to hold the newly aquired stock for 3 days.
$NVIV...that would be sweet.
$NVIV...took a boatload of shares to get this moving up but very few to move it down. MMs screwing with this one.
$NVIV...thanks, I've read that.
$NVIV lot of buying today but stock not moving.
$ETRM Typical buy the rumor, sell the news. Especially with biotech.
Thanks Bob. Too bad they all can't be winners.
$ETRM...yes, in @ 1.18, out @ 1.90
$ETRM in @ 1.18, sold @ 1.90, looking to buy back in @ lower price. Waiting for 1.45.
Sorry $heff doesn't like me anymore, can't post there. Wish I could.
http://1.usa.gov/1x0aFJ1
FDA approves first-of-kind device to treat obesity
$ETRM approved.
$ETRM approved.
$ETRM halted for news.
$ETRM halted for news.
Well said and oh so true.
Yeah I hear that. I only have 2k shares but it still will hurt.
$KBIO halted, news pending.
From flare9x on Sheff's board. Post #85047
ETRM - 1.36 -- Submits PMA June 25th: http://ir.enteromedics.com/releasedetail.cfm?releaseid=773470
FDA PMA Review Process: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm047991.htm
From FDA website: The 180-day period for review of a PMA starts on the date of filing.
For ETRM this 180 period starts from June 25th... almost 6 months from June 25 is about the Dec 25th period date....
$ETRM still holding 2k shares.
$KBIO Key Milestones for 2014-2015
2H 2014:
Full enrollment of KB001-A CF Phase 2 study (completed in July 2014)
Q4 2014:
December 2014:
Completion of enrollment in at least one indication in the Phase 2 expansion portion of our KB004 study in hematologic malignancies
KB004 Phase 1 study poster presentation at the American Society of Hematology Annual Meeting
January 2015:
Top line KB001-A CF Phase 2 study results
http://bit.ly/1zJ9bn9
$KMDA 3.65
$KMDA 3.88 + .18, +4.86%.
$BCRX FDA approves BioCryst's intravenous flu drug
Dec 22 (Reuters) - The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's intravenous flu drug, sending the company's shares up nearly 10 percent in premarket trading.
The single-dose drug is for adults who have acute uncomplicated influenza and may be unable to swallow pills, such as Gilead Sciences Inc's Tamiflu, or inhale GlaxoSmithKline Plc's Relenza.
"An IV (intravenous) drug would ensure that an appropriate dose is administered, which is a concern for oral and inhaled drugs in severely ill patients," Needham & Co analyst Serge Belanger said.
Biocryst's peramivir injection, to be sold as Rapivab, is the first antiviral influenza treatment approved by the FDA in fifteen years, the company said on Monday.
http://yhoo.it/1JIgVhh
$CUR NSI-566 spinal cord-derived stem cell therapy for the treatment of ALS
Neuralstem announced the last patient was treated in the current multicenter Phase II ALS clinical trial. This dose escalating trial treated 15 ambulatory patients in five different cohorts. Each of the three patients in the final cohort received a total of 40 injections of 400,000 cells in both the cervical and lumbar regions. The six-month observation period and data lock is scheduled to conclude in late January 2015 at which time the company anticipates providing its Phase II ALS results. - See more at: http://investor.neuralstem.com/index.php?s=43&item=196#sthash.hnWQLyZK.dpuf
http://investor.neuralstem.com/index.php?s=43&item=196
$BLUE 45.00 up almost 3 %. 4 days ago its low was 39.02.
$ETRM lot of selling today. 578,823 share sell this morning. Just watched a 17,000 share sell.